XTX Topco Ltd owns $145,000 in Resolute, Inc. (NASDAQ:RZLT)

XTX Topco Ltd increased its holdings in Resolute, Inc. (NASDAQ:RZLT – Free Report) by 205.8% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 33,671 shares of the company’s stock after buying an additional 22,660 shares during the quarter. XTX Topco Ltd owned 0.08% of Resolute worth $145,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the company. Jeppson Wealth Management LLC bought a new position in shares of Resolved in the second quarter valued at approximately $45,000. Virtu Financial LLC acquired a new position in Resolved in the first quarter valued at $37,000. Rosalind Advisors Inc. lifted its position in shares of Resolute by 25.0% during the second quarter. Rosalind Advisors Inc. now owns 250,000 shares of the company’s stock valued at $1,075,000 after acquiring an additional 50,000 shares during the period. Dimensional Fund Advisors LP acquired a new stake in shares of Resolved in the second quarter worth $255,000. Finally, Acadian Asset Management LLC bought a new position in shares of Resolved in the first quarter worth $229,000. Institutional investors own 82.97% of the company’s shares.

Resolute stock down 2.6%

NASDAQ RZLT opened at $4.85 on Tuesday. The company has a market cap of $194.65 million, a price-to-earnings ratio of -4.25 and a beta of 1.18. Resolute, Inc. has a 12-month low of $0.72 and a 12-month high of $6.10. The company’s fifty day moving average is $4.65 and its 200 day moving average is $3.87.

Resolute (NASDAQ:RZLT – Get Your Free Report ) last announced its quarterly earnings results on Thursday, September 19th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.14). On average, research analysts anticipate that Resolute, Inc. will post -1.38 earnings per share for the current fiscal year.

The Wall Street analyst weighs in

A number of equities research analysts have issued reports on the stock. Maxim Group boosted their price objective on shares of Resolute from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and issued a $14.00 price objective on shares of Resolve in a research note on Friday. Craig Hallum initiated coverage on shares of Resolved in a research report on Tuesday, June 4th. They set a “buy” rating and a $14.00 price objective for the company. BTIG Research lifted their price target on Resolute from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, September 10th. Finally, JMP Securities reissued a “market outperform” rating and set a $7.00 target price on shares of Resolve in a report on Friday, September 20th. Seven analysts have rated the stock with a buy rating. The stock currently has a consensus rating of “Buy” and a consensus price target of $11.57, according to MarketBeat.

See the latest stock analysis on RZLT

About Resolutions

(Free Report)

Resolute, Inc, a clinical-stage biopharmaceutical company, is developing therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company’s lead product candidate is RZ358, a human monoclonal antibody that is in a Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

Featured stories

Get news and reviews for Resolute Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Resolved and related companies with MarketBeat.com’s FREE daily email newsletter.